On 21 May 2026, the National Advertising Review Board (NARB) issued a decision upholding the NAD (National Advertising Division) recommendation in Case #7487 concerning the dietary supplement Tru Niagen manufactured by Niagen Bioscience. NARB recommended that the manufacturer modify or discontinue the claim that the supplement is "clinically proven" to raise NAD+ levels in the general population. Although this case was decided within the American advertising self-regulatory system, it provides valuable lessons for Polish and European dietary supplement manufacturers.
Who Are NAD and NARB? The American Advertising Self-Regulatory System
NAD (National Advertising Division) is an advertising self-regulatory body operating within BBB National Programs in the United States. It is not a court, not a government body and does not issue judgments. NAD examines the truthfulness and reliability of advertising claims based on competitor or consumer complaints, or on its own initiative.
NARB (National Advertising Review Board) serves as the appellate body from NAD decisions. It consists of panels composed of representatives from the advertising industry, advertisers and academia. NARB decisions are final within the self-regulatory system.
The key difference from European systems: NAD/NARB decisions are recommendations, not administrative decisions. However, non-compliance results in referral to the FTC (Federal Trade Commission), which has the power to impose financial sanctions and court orders. In practice, over 95% of advertisers comply with NAD/NARB recommendations.
- NAD - National Advertising Division (first-instance body, examines advertising claims)
- NARB - National Advertising Review Board (appellate body, upholds or reverses NAD decisions)
- FTC - Federal Trade Commission (government body with enforcement powers)
- BBB National Programs - parent organisation, equivalent of industry self-regulation
The Tru Niagen Case (NAD Case #7487)
The subject of NAD Case #7487 was the dietary supplement Tru Niagen manufactured by Niagen Bioscience. The product contains nicotinamide riboside (NR) - a precursor of NAD+ (nicotinamide adenine dinucleotide), a coenzyme playing a key role in cellular metabolism.
Niagen Bioscience advertised Tru Niagen using the claim "clinically proven to raise NAD+ levels", suggesting that this effect was scientifically proven for the general consumer population.
NAD challenged this claim for the following reasons:
- Clinical studies were conducted on a limited, specific research population
- Extrapolation of results to the general population was not sufficiently scientifically justified
- The phrase "clinically proven" suggests universality and certainty of effect that the scientific data did not confirm
- The difference between "studies suggest" and "clinically proven" has significant implications for consumer expectations
In its decision of 21 May 2026, NARB upheld NAD's position and recommended that Niagen Bioscience modify or entirely discontinue use of the challenged claim.
Legal Basis in the USA: DSHEA and FTC Act
Regulation of dietary supplements in the USA is based on two pillars:
- DSHEA (Dietary Supplement Health and Education Act, 1994) - classifies supplements as food, does not require pre-market FDA authorisation, but prohibits claims of medicinal properties. It permits so-called structure/function claims (claims about effects on body structure/function) provided there is scientific substantiation.
- FTC Act (Section 5) - prohibits unfair or misleading advertising practices. The FTC requires that advertising claims for supplements be supported by "competent and reliable scientific evidence".
The NAD/NARB system operates in parallel with government regulation - as an industry self-regulatory mechanism applying standards similar to FTC requirements, but through a faster and less costly procedure than court or administrative proceedings.
Important Note: NAD (National Advertising Division) should not be confused with the Polish abbreviation NSA (Naczelny Sad Administracyjny - Supreme Administrative Court). These are entirely different institutions in different legal systems. NAD is a private advertising self-regulatory body in the USA, while the Supreme Administrative Court (NSA) is the highest instance of administrative courts in Poland.
Comparison with EU Regulations: Regulation (EC) No 1924/2006
For European manufacturers, it is crucial to understand that EU regulations on health claims are significantly more restrictive than the American self-regulatory system. Here are the key differences:
The EU Health Claims Authorisation System
In the EU, Regulation (EC) No 1924/2006 applies, introducing a closed system: manufacturers may only use those health claims that have been authorised by the European Commission based on an EFSA Scientific Opinion and entered in the EU Register. There is no equivalent of American "structure/function claims" - every claim linking the product to health requires authorisation.
"Clinically Proven" in the Context of EU Law
The phrase "clinically proven" in relation to a dietary supplement under EU law:
- Constitutes an unauthorised health claim if it suggests a link to a specific health effect
- Violates Art. 10(1) of Regulation 1924/2006 (prohibition of unauthorised health claims)
- May constitute an unfair commercial practice within the meaning of Directive 2005/29/EC
- Is subject to sanctions by national authorities (in Poland: the Office of Competition and Consumer Protection (UOKiK), the Chief Sanitary Inspectorate (GIS))
Systemic Differences: USA vs. EU
- USA: open system - manufacturers may use claims provided they have scientific substantiation; control occurs post factum (through NAD/NARB or FTC)
- EU: closed system - manufacturers may only use claims from the EU Register; control is preventive
- USA: industry self-regulation (NAD/NARB) + government oversight (FTC)
- EU: exclusively government oversight (national authorities + European Commission)
- USA: recommendation to modify/discontinue (no direct financial sanction)
- EU: administrative decisions with sanctions up to 10% of turnover (UOKiK in Poland)
Expert Advice: If the American self-regulatory system challenged the "clinically proven" claim as insufficiently substantiated, it will all the more fail verification under the EU system, where even a fully scientifically documented claim requires formal EFSA authorisation. Manufacturers exporting from the EU to the USA should assume that the EU standard is stricter, and if their communication meets EU requirements, it will with high probability also meet American requirements.
Enforcement in Poland: UOKiK and GIS
In Poland, oversight of dietary supplement health claims is exercised primarily by:
- Office of Competition and Consumer Protection (UOKiK) - issues decisions finding violations of collective consumer interests, may impose fines up to 10% of entrepreneur's turnover. Actively monitors supplement advertising.
- Chief Sanitary Inspectorate (GIS) - oversees compliance of supplement labelling and advertising with food safety regulations, including Regulation 1924/2006.
- Trade Inspection - inspects the market for unfair commercial practices.
In recent years, UOKiK has conducted numerous proceedings concerning unauthorised health claims in dietary supplement advertising, imposing fines reaching several million PLN. The phrase "clinically proven" without EFSA authorisation is a typical violation identified by these authorities.
Practical Conclusions for European Manufacturers
The NARB decision in the Tru Niagen case, although issued within the American self-regulatory system, should serve as a warning for supplement manufacturers operating in international markets. Here are the key conclusions:
- Avoid the phrase "clinically proven" - both in the EU market (where it is expressly prohibited without authorisation) and in the US market (where it may be challenged by NAD/FTC)
- Use only authorised health claims from the EU Register in the European market
- In the US market, use structure/function claims with solid scientific substantiation, avoiding phrases suggesting universality of effect
- Distinguish the study population from the target population - results of a study on a specific group do not justify claims about the general population
- Prepare a separate communication strategy for the EU and US markets, accounting for regulatory differences
- Monitor NAD/NARB decisions - they may signal the direction in which European supervisory authorities are also heading
Alternative Phrases Compliant with EU Law
- Authorised health claims from the EU Register (e.g., "Niacin contributes to normal energy-yielding metabolism")
- Reference to a specific study with full source citation: "A study published in [journal], [year], showed..."
- Nutrition claims (e.g., vitamin/mineral content) compliant with Regulation 1924/2006
- Information about composition and dosage without suggesting a health effect
Alternative Phrases for the US Market
- Structure/function claims with disclaimer: "This statement has not been evaluated by the FDA..."
- Reference to specific study parameters instead of the general "clinically proven"
- Precise identification of the population for which the effect was demonstrated
- Formulations such as "studies suggest" instead of "clinically proven"
Expert Advice: The Tru Niagen case shows that even in the less restrictive American system, the "clinically proven" claim was challenged. European manufacturers exporting to the USA should treat NAD/NARB decisions as an additional argument for caution in marketing communication. I recommend conducting an audit of all advertising materials for compliance with both Regulation 1924/2006 (EU market) and FTC/DSHEA requirements (US market).